ALUMIS INC. Logo

ALUMIS INC.

Develops targeted oral therapies for immune-mediated diseases using precision immunology.

ALMS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
280 EAST GRAND AVENUE, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases. The company utilizes a precision immunology approach, powered by a proprietary data analytics platform, to drive smarter therapeutic development. Alumis is advancing a late-stage portfolio of next-generation targeted oral therapies designed to replace broad immunosuppression with treatments that address the key drivers of immune dysfunction. Its mission is to optimize patient outcomes and significantly improve the lives of individuals with autoimmune conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALUMIS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALUMIS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALUMIS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA

Talk to a Data Expert

Have a question? We'll get back to you promptly.